{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:45:20Z","timestamp":1769834720538,"version":"3.49.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s11886-023-01954-y","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T12:02:15Z","timestamp":1694520135000},"page":"1361-1371","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Update on Transcatheter Treatment of Mitral and Tricuspid Valve Regurgitation"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5524-5844","authenticated-orcid":false,"given":"David","family":"Meier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariama","family":"Akodad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Tzimas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Muller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anson","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Blanke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janarthanan","family":"Sathananthan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabien","family":"Praz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert H.","family":"Boone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,12]]},"reference":[{"key":"1954_CR1","doi-asserted-by":"crossref","unstructured":"Tung M, Nah G, Tang J, Marcus G, Delling FN. Valvular disease burden in the modern era of percutaneous and surgical interventions: the UK Biobank. Open Heart 2022;9.","DOI":"10.1136\/openhrt-2022-002039"},{"key":"1954_CR2","first-page":"e35","volume":"143","author":"CM Otto","year":"2021","unstructured":"Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC\/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143:e35\u201371.","journal-title":"Circulation"},{"key":"1954_CR3","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","volume":"43","author":"A Vahanian","year":"2022","unstructured":"Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC\/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2022;43:561\u2013632.","journal-title":"Eur Heart J"},{"key":"1954_CR4","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1016\/j.jacc.2021.07.058","volume":"78","author":"M Mack","year":"2021","unstructured":"Mack M, Carroll JD, Thourani V, et al. Transcatheter mitral valve therapy in the United States: a report from the STS-ACC TVT Registry. J Am Coll Cardiol. 2021;78:2326\u201353.","journal-title":"J Am Coll Cardiol"},{"key":"1954_CR5","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1056\/NEJMoa2300213","volume":"388","author":"GW Stone","year":"2023","unstructured":"Stone GW, Abraham WT, Lindenfeld J, et al. Five-year follow-up after transcatheter repair of secondary mitral regurgitation. N Engl J Med. 2023;388:2037\u201348.","journal-title":"N Engl J Med"},{"key":"1954_CR6","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.cjca.2021.12.003","volume":"38","author":"A Scotti","year":"2022","unstructured":"Scotti A, Munafo A, Adamo M, et al. Transcatheter edge-to-edge repair in COAPT-ineligible patients: incidence and predictors of 2-year good outcome. Can J Cardiol. 2022;38:320\u20139.","journal-title":"Can J Cardiol"},{"key":"1954_CR7","doi-asserted-by":"publisher","first-page":"957","DOI":"10.4244\/EIJ-D-22-00725","volume":"18","author":"J Hausleiter","year":"2023","unstructured":"Hausleiter J, Stocker TJ, Adamo M, Karam N, Swaans MJ, Praz F. Mitral valve transcatheter edge-to-edge repair. EuroIntervention. 2023;18:957\u201376.","journal-title":"EuroIntervention"},{"key":"1954_CR8","doi-asserted-by":"crossref","unstructured":"D. Scott Lim HCH, Paul Grayburn, Konstantinos Koulogiannis, Gorav Ailawadi,, Mathew Williams VGN, Katherine H. Chau, Paul Sorajja, Robert L. Smith II,, Mayra Guerrero DD, Juan F. Granada, Michael J. Mack, Martin B. Leon,, Patrick McCarthy. Consensus document on non-suitability for transcatheter mitral valve repair by edge-to-edge therapy. STRUCTURAL HEART 2021;VOL. 5, NO. 3, 227\u2013233.","DOI":"10.1080\/24748706.2021.1902595"},{"issue":"86\u201394","key":"1954_CR9","volume":"158","author":"N Buzzatti","year":"2019","unstructured":"Buzzatti N, Van Hemelrijck M, Denti P, et al. Transcatheter or surgical repair for degenerative mitral regurgitation in elderly patients: a propensity-weighted analysis. J Thorac Cardiovasc Surg. 2019;158(86\u201394): e1.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"1954_CR10","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa1009355","volume":"364","author":"T Feldman","year":"2011","unstructured":"Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011;364:1395\u2013406.","journal-title":"N Engl J Med"},{"key":"1954_CR11","first-page":"1980","volume":"380","author":"GW Stone","year":"2019","unstructured":"Stone GW, Weissman NJ, Mack MJ, Investigators C. Transcatheter mitral-valve repair in patients with heart failure. Reply N Engl J Med. 2019;380:1980\u20131.","journal-title":"Reply N Engl J Med"},{"key":"1954_CR12","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.jcin.2019.02.039","volume":"12","author":"AK Chhatriwalla","year":"2019","unstructured":"Chhatriwalla AK, Vemulapalli S, Holmes DR Jr, et al. Institutional experience with transcatheter mitral valve repair and clinical outcomes: insights from the TVT Registry. JACC Cardiovasc Interv. 2019;12:1342\u201352.","journal-title":"JACC Cardiovasc Interv"},{"key":"1954_CR13","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.jcin.2023.05.013","volume":"16","author":"RS von Bardeleben","year":"2023","unstructured":"\u2022\u2022 von Bardeleben RS, Rogers JH, Mahoney P, et al. Real-world outcomes of fourth-generation mitral transcatheter repair: 30-day results from EXPAND G4. JACC Cardiovasc Interv. 2023;16:1463\u201373. Large all-comers registry of contemporary outcomes of M-TEER using fourth generation MitraClip.","journal-title":"JACC Cardiovasc Interv"},{"key":"1954_CR14","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jcin.2023.01.010","volume":"16","author":"S Kar","year":"2023","unstructured":"Kar S, von Bardeleben RS, Rottbauer W, et al. Contemporary outcomes following transcatheter edge-to-edge repair: 1-year results from the EXPAND Study. JACC Cardiovasc Interv. 2023;16:589\u2013602.","journal-title":"JACC Cardiovasc Interv"},{"key":"1954_CR15","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.jcin.2021.04.001","volume":"14","author":"M Szerlip","year":"2021","unstructured":"Szerlip M, Spargias KS, Makkar R, et al. 2-year outcomes for transcatheter repair in patients with mitral regurgitation from the CLASP Study. JACC Cardiovasc Interv. 2021;14:1538\u201348.","journal-title":"JACC Cardiovasc Interv"},{"key":"1954_CR16","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1016\/j.jcin.2022.10.008","volume":"15","author":"V Mauri","year":"2022","unstructured":"Mauri V, Sugiura A, Spieker M, et al. Early outcomes of 2 mitral valve transcatheter leaflet approximation devices: a propensity score-matched multicenter comparison. JACC Cardiovasc Interv. 2022;15:2541\u201351.","journal-title":"JACC Cardiovasc Interv"},{"key":"1954_CR17","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1016\/j.jcin.2022.09.005","volume":"15","author":"DS Lim","year":"2022","unstructured":"Lim DS, Smith RL, Gillam LD, et al. Randomized comparison of transcatheter edge-to-edge repair for degenerative mitral regurgitation in prohibitive surgical risk patients. JACC Cardiovasc Interv. 2022;15:2523\u201336.","journal-title":"JACC Cardiovasc Interv"},{"key":"1954_CR18","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/ehf2.13849","volume":"9","author":"NA Geis","year":"2022","unstructured":"Geis NA, Schlegel P, Heckmann MB, Katus HA, Frey N, Crespo Lopez P, Raake PWJ. One-year results following PASCAL-based or MitraClip-based mitral valve transcatheter edge-to-edge repair. ESC Heart Fail. 2022;9:853\u201365.","journal-title":"ESC Heart Fail"},{"key":"1954_CR19","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.jcin.2021.09.024","volume":"14","author":"P Luedike","year":"2021","unstructured":"Luedike P, Riebisch M, Schindhelm F, et al. Impact of mitral valve repair technologies on predictability of post-delivery residual mitral regurgitation. JACC Cardiovasc Interv. 2021;14:2638\u201340.","journal-title":"JACC Cardiovasc Interv"},{"key":"1954_CR20","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1016\/j.jacc.2017.09.015","volume":"70","author":"P Sorajja","year":"2017","unstructured":"Sorajja P, Vemulapalli S, Feldman T, et al. Outcomes with transcatheter mitral valve repair in the United States: an STS\/ACC TVT Registry Report. J Am Coll Cardiol. 2017;70:2315\u201327.","journal-title":"J Am Coll Cardiol"},{"key":"1954_CR21","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/j.jcin.2023.05.014","volume":"16","author":"JH Rogers","year":"2023","unstructured":"Rogers JH, Asch F, Sorajja P, et al. Expanding the spectrum of TEER suitability: evidence from the EXPAND G4 post approval study. JACC Cardiovasc Interv. 2023;16:1474\u201385.","journal-title":"JACC Cardiovasc Interv"},{"key":"1954_CR22","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jacc.2022.11.034","volume":"81","author":"J Hausleiter","year":"2023","unstructured":"Hausleiter J, Lim DS, Gillam LD, et al. Transcatheter edge-to-edge repair in patients with anatomically complex degenerative mitral regurgitation. J Am Coll Cardiol. 2023;81:431\u201342.","journal-title":"J Am Coll Cardiol"},{"key":"1954_CR23","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jacasi.2022.03.010","volume":"2","author":"X Liu","year":"2022","unstructured":"Liu X, Chen M, Han Y, et al. First-in-human study of the novel transcatheter mitral valve repair system for mitral regurgitation. JACC Asia. 2022;2:390\u20134.","journal-title":"JACC Asia"},{"key":"1954_CR24","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1053\/j.jvca.2022.05.005","volume":"36","author":"D Khatib","year":"2022","unstructured":"Khatib D, Neuburger PJ, Pan S, Rong LQ. Transcatheter mitral valve interventions for mitral regurgitation: a review of mitral annuloplasty, valve replacement, and chordal repair devices. J Cardiothorac Vasc Anesth. 2022;36:3887\u2013903.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"1954_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.641691","volume":"8","author":"M Chen","year":"2021","unstructured":"Chen M, Sun L. What is the next generation of transcatheter mitral valve repair devices? Front Cardiovasc Med. 2021;8: 641691.","journal-title":"Front Cardiovasc Med"},{"key":"1954_CR26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jchf.2021.03.002","volume":"9","author":"SD Anker","year":"2021","unstructured":"Anker SD, Starling RC, Khan MS, et al. Percutaneous mitral valve annuloplasty in patients with secondary mitral regurgitation and severe left ventricular enlargement. JACC Heart Fail. 2021;9:453\u201362.","journal-title":"JACC Heart Fail"},{"key":"1954_CR27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.21037\/acs-2020-mv-86","volume":"10","author":"G Gerosa","year":"2021","unstructured":"Gerosa G, Nadali M, Longinotti L, et al. Transapical off-pump echo-guided mitral valve repair with neochordae implantation mid-term outcomes. Ann Cardiothorac Surg. 2021;10:131\u201340.","journal-title":"Ann Cardiothorac Surg"},{"key":"1954_CR28","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.jcin.2017.05.032","volume":"10","author":"A Regueiro","year":"2017","unstructured":"Regueiro A, Ye J, Fam N, et al. 2-year outcomes after transcatheter mitral valve replacement. JACC Cardiovasc Interv. 2017;10:1671\u20138.","journal-title":"JACC Cardiovasc Interv"},{"key":"1954_CR29","doi-asserted-by":"publisher","first-page":"787","DOI":"10.21037\/acs.2018.09.05","volume":"7","author":"A Cheung","year":"2018","unstructured":"Cheung A. Early experience of TIARA transcatheter mitral valve replacement system. Ann Cardiothorac Surg. 2018;7:787\u201391.","journal-title":"Ann Cardiothorac Surg"},{"key":"1954_CR30","first-page":"1222","volume":"18","author":"DJ Cohen","year":"2023","unstructured":"Cohen DJ, Ludwig S, Piazza N. Transcatheter mitral valve replacement will remain a niche therapy: pros and cons. EuroIntervention. 2023;18:1222\u20135.","journal-title":"EuroIntervention"},{"key":"1954_CR31","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1016\/j.jacc.2021.04.051","volume":"77","author":"A Alperi","year":"2021","unstructured":"Alperi A, Granada JF, Bernier M, Dagenais F, Rodes-Cabau J. Current status and future prospects of transcatheter mitral valve replacement: JACC state-of-the-art review. J Am Coll Cardiol. 2021;77:3058\u201378.","journal-title":"J Am Coll Cardiol"},{"key":"1954_CR32","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Ludwig S, Perrin N, Coisne A et al. Clinical outcomes of transcatheter mitral valve replacement: two-year results of the CHOICE-MI Registry. EuroIntervention 2023. Largest TMVR registry to date, illustrating clinical benefits but also challenges of TMVR.","DOI":"10.4244\/EIJ-D-22-01037"},{"key":"1954_CR33","doi-asserted-by":"publisher","first-page":"1130212","DOI":"10.3389\/fcvm.2023.1130212","volume":"10","author":"A Alperi","year":"2023","unstructured":"Alperi A, Avanzas P, Leon V, et al. Current status of transcatheter mitral valve replacement: systematic review and meta-analysis. Front Cardiovasc Med. 2023;10:1130212.","journal-title":"Front Cardiovasc Med"},{"key":"1954_CR34","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/ejhf.2434","volume":"24","author":"MG Wild","year":"2022","unstructured":"Wild MG, Kreidel F, Hell MM, et al. Transapical mitral valve implantation for treatment of symptomatic mitral valve disease: a real-world multicentre experience. Eur J Heart Fail. 2022;24:899\u2013907.","journal-title":"Eur J Heart Fail"},{"key":"1954_CR35","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/j.jacc.2021.08.060","volume":"78","author":"DWM Muller","year":"2021","unstructured":"Muller DWM, Sorajja P, Duncan A, et al. 2-year outcomes of transcatheter mitral valve replacement in patients with severe symptomatic mitral regurgitation. J Am Coll Cardiol. 2021;78:1847\u201359.","journal-title":"J Am Coll Cardiol"},{"key":"1954_CR36","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1016\/j.jacc.2021.08.062","volume":"78","author":"J Rodes-Cabau","year":"2021","unstructured":"Rodes-Cabau J, Regueiro A, Mack MJ. Transcatheter mitral valve replacement: a need for better patient selection. J Am Coll Cardiol. 2021;78:1860\u20132.","journal-title":"J Am Coll Cardiol"},{"key":"1954_CR37","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.123.013045","volume":"16","author":"S Ludwig","year":"2023","unstructured":"Ludwig S, Conradi L, Cohen DJ, et al. Transcatheter mitral valve replacement versus medical therapy for secondary mitral regurgitation: a propensity score-matched comparison. Circ Cardiovasc Interv. 2023;16: e013045.","journal-title":"Circ Cardiovasc Interv"},{"key":"1954_CR38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jacc.2017.10.061","volume":"71","author":"V Bapat","year":"2018","unstructured":"Bapat V, Rajagopal V, Meduri C, et al. Early experience with new transcatheter mitral valve replacement. J Am Coll Cardiol. 2018;71:12\u201321.","journal-title":"J Am Coll Cardiol"},{"key":"1954_CR39","doi-asserted-by":"crossref","unstructured":"Makkar R ONW, Whisenant B, et al. Updated 30-Day Outcomes for the U.S. Early feasibility study of the SAPIEN M3 transcatheter mitral valve replacement system. J Am Coll Cardiol 2019;Sep 1;74(13):B8.","DOI":"10.1016\/j.jacc.2019.08.030"},{"key":"1954_CR40","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jaccas.2019.10.034","volume":"1","author":"SS Goel","year":"2019","unstructured":"Goel SS, Zuck V, Christy J, Nallamothu N, Jagtap P, Gao J, Goswami NJ. Transcatheter mitral valve therapy with novel supra-annular AltaValve: first experience in the United States. JACC Case Rep. 2019;1:761\u20134.","journal-title":"JACC Case Rep"},{"key":"1954_CR41","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1016\/j.jcin.2020.06.040","volume":"13","author":"J Webb","year":"2020","unstructured":"Webb J, Hensey M, Fam N, et al. Transcatheter mitral valve replacement with the transseptal EVOQUE system. JACC Cardiovasc Interv. 2020;13:2418\u201326.","journal-title":"JACC Cardiovasc Interv"},{"key":"1954_CR42","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1016\/j.jcin.2020.08.006","volume":"13","author":"A Alperi","year":"2020","unstructured":"Alperi A, Dagenais F, Del Val D, et al. Early experience with a novel transfemoral mitral valve implantation system in complex degenerative mitral regurgitation. JACC Cardiovasc Interv. 2020;13:2427\u201337.","journal-title":"JACC Cardiovasc Interv"},{"key":"1954_CR43","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jcin.2018.10.042","volume":"12","author":"H Niikura","year":"2019","unstructured":"Niikura H, Gossl M, Kshettry V, et al. Causes and clinical outcomes of patients who are ineligible for transcatheter mitral valve replacement. JACC Cardiovasc Interv. 2019;12:196\u2013204.","journal-title":"JACC Cardiovasc Interv"},{"key":"1954_CR44","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/ejhf.2492","volume":"24","author":"W Ben Ali","year":"2022","unstructured":"Ben Ali W, Ludwig S, Duncan A, et al. Characteristics and outcomes of patients screened for transcatheter mitral valve implantation: 1-year results from the CHOICE-MI registry. Eur J Heart Fail. 2022;24:887\u201398.","journal-title":"Eur J Heart Fail"},{"key":"1954_CR45","doi-asserted-by":"publisher","first-page":"e983","DOI":"10.4244\/EIJ-D-19-00444","volume":"15","author":"A Coisne","year":"2019","unstructured":"Coisne A, Pontana F, Tchetche D, et al. Transcatheter mitral valve replacement: factors associated with screening success and failure. EuroIntervention. 2019;15:e983\u20139.","journal-title":"EuroIntervention"},{"key":"1954_CR46","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.jcin.2023.01.357","volume":"16","author":"MF Eleid","year":"2023","unstructured":"Eleid MF, Collins JD, Mahoney P, et al. Emerging approaches to management of left ventricular outflow obstruction risk in transcatheter mitral valve replacement. JACC Cardiovasc Interv. 2023;16:885\u201395.","journal-title":"JACC Cardiovasc Interv"},{"key":"1954_CR47","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/ejhf.2797","volume":"25","author":"S Ludwig","year":"2023","unstructured":"Ludwig S, Kalbacher D, Ali WB, et al. Transcatheter mitral valve replacement or repair for secondary mitral regurgitation: a propensity score-matched analysis. Eur J Heart Fail. 2023;25:399\u2013410.","journal-title":"Eur J Heart Fail"},{"key":"1954_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.101684","volume":"48","author":"M Al-Tawil","year":"2023","unstructured":"Al-Tawil M, Butt S, Reap S, et al. Transseptal vs transapical transcatheter mitral valve-in-valve and valve-in-ring implantation: a systematic review and meta-analysis. Curr Probl Cardiol. 2023;48: 101684.","journal-title":"Curr Probl Cardiol"},{"key":"1954_CR49","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.jcin.2021.02.027","volume":"14","author":"M Guerrero","year":"2021","unstructured":"Guerrero M, Pursnani A, Narang A, et al. Prospective evaluation of transseptal TMVR for failed surgical bioprostheses: MITRAL trial valve-in-valve arm 1-year outcomes. JACC Cardiovasc Interv. 2021;14:859\u201372.","journal-title":"JACC Cardiovasc Interv"},{"key":"1954_CR50","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/jamacardio.2020.2974","volume":"5","author":"B Whisenant","year":"2020","unstructured":"Whisenant B, Kapadia SR, Eleid MF, et al. One-year outcomes of mitral valve-in-valve using the SAPIEN 3 transcatheter heart valve. JAMA Cardiol. 2020;5:1245\u201352.","journal-title":"JAMA Cardiol"},{"key":"1954_CR51","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1016\/j.jacc.2022.09.037","volume":"80","author":"MF Eleid","year":"2022","unstructured":"Eleid MF, Wang DD, Pursnani A, et al. 2-year outcomes of transcatheter mitral valve replacement in patients with annular calcification, rings, and bioprostheses. J Am Coll Cardiol. 2022;80:2171\u201383.","journal-title":"J Am Coll Cardiol"},{"key":"1954_CR52","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1161\/CIRCULATIONAHA.120.049088","volume":"143","author":"M Simonato","year":"2021","unstructured":"Simonato M, Whisenant B, Ribeiro HB, et al. Transcatheter mitral valve replacement after surgical repair or replacement: comprehensive midterm evaluation of valve-in-valve and valve-in-ring implantation from the VIVID Registry. Circulation. 2021;143:104\u201316.","journal-title":"Circulation"},{"key":"1954_CR53","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.pcad.2019.10.009","volume":"62","author":"M Enriquez-Sarano","year":"2019","unstructured":"Enriquez-Sarano M, Messika-Zeitoun D, Topilsky Y, Tribouilloy C, Benfari G, Michelena H. Tricuspid regurgitation is a public health crisis. Prog Cardiovasc Dis. 2019;62:447\u201351.","journal-title":"Prog Cardiovasc Dis"},{"key":"1954_CR54","doi-asserted-by":"publisher","first-page":"840","DOI":"10.4244\/EIJ-D-22-00442","volume":"18","author":"A Scotti","year":"2022","unstructured":"Scotti A, Sturla M, Granada JF, et al. Outcomes of isolated tricuspid valve replacement: a systematic review and meta-analysis of 5,316 patients from 35 studies. EuroIntervention. 2022;18:840\u201351.","journal-title":"EuroIntervention"},{"key":"1954_CR55","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.1093\/eurheartj\/ehaa643","volume":"41","author":"J Dreyfus","year":"2020","unstructured":"Dreyfus J, Flagiello M, Bazire B, et al. Isolated tricuspid valve surgery: impact of aetiology and clinical presentation on outcomes. Eur Heart J. 2020;41:4304\u201317.","journal-title":"Eur Heart J"},{"key":"1954_CR56","doi-asserted-by":"crossref","unstructured":"Groger M, Friedl S, Ouerghemmi D et al. TRI-SCORE is superior to EuroSCORE II and STS-Score in mortality prediction following transcatheter edge-to-edge tricuspid valve repair. Clin Res Cardiol 2023.","DOI":"10.1007\/s00392-023-02246-9"},{"key":"1954_CR57","doi-asserted-by":"crossref","unstructured":"Vogelhuber J, Tanaka T, Sugiura A et al. Association of TRI-SCORE with clinical outcomes after transcatheter tricuspid valve repair. JACC Cardiovasc Interv 2023.","DOI":"10.1016\/j.jcin.2023.04.005"},{"key":"1954_CR58","doi-asserted-by":"crossref","unstructured":"Lurz P, Stephan von Bardeleben R, Weber M et al. Transcatheter edge-to-edge repair for treatment of tricuspid regurgitation. J Am Coll Cardiol 2021;77:229\u2013239.","DOI":"10.1016\/j.jacc.2020.11.038"},{"key":"1954_CR59","doi-asserted-by":"crossref","unstructured":"Lurz P, Besler C, Schmitz T et al. Short-term outcomes of tricuspid edge-to-edge repair in clinical practice. J Am Coll Cardiol 2023.","DOI":"10.1016\/j.jacc.2023.05.008"},{"key":"1954_CR60","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1056\/NEJMoa2300525","volume":"388","author":"P Sorajja","year":"2023","unstructured":"\u2022\u2022 Sorajja P, Whisenant B, Hamid N, et al. Transcatheter repair for patients with tricuspid regurgitation. N Engl J Med. 2023;388:1833\u201342. Pivotal randomized trial on TEER versus medical management for severe TR.","journal-title":"N Engl J Med"},{"key":"1954_CR61","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jcin.2017.12.004","volume":"11","author":"NP Fam","year":"2018","unstructured":"Fam NP, Ho EC, Zahrani M, Samargandy S, Connelly KA. Transcatheter tricuspid valve repair with the PASCAL system. JACC Cardiovasc Interv. 2018;11:407\u20138.","journal-title":"JACC Cardiovasc Interv"},{"key":"1954_CR62","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1016\/j.jcin.2019.09.046","volume":"12","author":"NP Fam","year":"2019","unstructured":"Fam NP, Braun D, von Bardeleben RS, et al. Compassionate use of the PASCAL transcatheter valve repair system for severe tricuspid regurgitation: a multicenter, observational, first-in-human experience. JACC Cardiovasc Interv. 2019;12:2488\u201395.","journal-title":"JACC Cardiovasc Interv"},{"key":"1954_CR63","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jacc.2020.11.047","volume":"77","author":"S Kodali","year":"2021","unstructured":"Kodali S, Hahn RT, Eleid MF, et al. Feasibility study of the transcatheter valve repair system for severe tricuspid regurgitation. J Am Coll Cardiol. 2021;77:345\u201356.","journal-title":"J Am Coll Cardiol"},{"key":"1954_CR64","doi-asserted-by":"publisher","first-page":"e1264","DOI":"10.4244\/EIJ-D-20-01107","volume":"16","author":"G Nickenig","year":"2021","unstructured":"Nickenig G, Weber M, Schuler R, et al. Tricuspid valve repair with the Cardioband system: two-year outcomes of the multicentre, prospective TRI-REPAIR study. EuroIntervention. 2021;16:e1264\u201371.","journal-title":"EuroIntervention"},{"key":"1954_CR65","doi-asserted-by":"publisher","first-page":"809","DOI":"10.4244\/EIJ-D-21-00300","volume":"17","author":"G Nickenig","year":"2021","unstructured":"Nickenig G, Friedrichs KP, Baldus S, et al. Thirty-day outcomes of the Cardioband tricuspid system for patients with symptomatic functional tricuspid regurgitation: the TriBAND study. EuroIntervention. 2021;17:809\u201317.","journal-title":"EuroIntervention"},{"key":"1954_CR66","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1016\/j.jacc.2023.04.014","volume":"81","author":"L Stolz","year":"2023","unstructured":"Stolz L, Weckbach LT, Hahn RT, et al. 2-year outcomes following transcatheter tricuspid valve replacement using the EVOQUE system. J Am Coll Cardiol. 2023;81:2374\u20136.","journal-title":"J Am Coll Cardiol"},{"key":"1954_CR67","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jcin.2022.01.280","volume":"15","author":"JG Webb","year":"2022","unstructured":"Webb JG, Chuang AM, Meier D, et al. Transcatheter tricuspid valve replacement with the EVOQUE system: 1-year outcomes of a multicenter, first-in-human experience. JACC Cardiovasc Interv. 2022;15:481\u201391.","journal-title":"JACC Cardiovasc Interv"},{"key":"1954_CR68","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jcin.2022.01.016","volume":"15","author":"S Kodali","year":"2022","unstructured":"Kodali S, Hahn RT, George I, et al. Transfemoral tricuspid valve replacement in patients with tricuspid regurgitation: TRISCEND study 30-day results. JACC Cardiovasc Interv. 2022;15:471\u201380.","journal-title":"JACC Cardiovasc Interv"},{"key":"1954_CR69","doi-asserted-by":"publisher","first-page":"862","DOI":"10.4244\/EIJ-D-22-00277","volume":"18","author":"E Teiger","year":"2022","unstructured":"Teiger E, Nejjari M, Lim P, et al. First-in-human implantation of the Topaz transcatheter tricuspid valve replacement system. EuroIntervention. 2022;18:862\u20134.","journal-title":"EuroIntervention"},{"key":"1954_CR70","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1136\/heartjnl-2020-318199","volume":"107","author":"FL Lu","year":"2021","unstructured":"Lu FL, An Z, Ma Y, et al. Transcatheter tricuspid valve replacement in patients with severe tricuspid regurgitation. Heart. 2021;107:1664\u201370.","journal-title":"Heart"},{"key":"1954_CR71","doi-asserted-by":"crossref","unstructured":"Zhang Y, Lu F, Li W et al. A first-in-human study of transjugular transcatheter tricuspid valve replacement with the LuX-Valve Plus system. EuroIntervention 2022.","DOI":"10.4244\/EIJ-D-22-00517"},{"key":"1954_CR72","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.jcin.2022.05.022","volume":"15","author":"R Estevez-Loureiro","year":"2022","unstructured":"Estevez-Loureiro R, Sanchez-Recalde A, Amat-Santos IJ, et al. 6-month outcomes of the tricvalve system in patients with tricuspid regurgitation: the TRICUS EURO study. JACC Cardiovasc Interv. 2022;15:1366\u201377.","journal-title":"JACC Cardiovasc Interv"},{"key":"1954_CR73","doi-asserted-by":"crossref","unstructured":"Amat-Santos IJ, Estevez-Loureiro R, Sanchez-Recalde A et al. Right heart remodelling after bicaval TricValve implantation in patients with severe tricuspid regurgitation. EuroIntervention 2023.","DOI":"10.4244\/EIJ-D-23-00077"},{"key":"1954_CR74","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.121.011302","volume":"15","author":"MG Wild","year":"2022","unstructured":"Wild MG, Lubos E, Cruz-Gonzalez I, et al. Early clinical experience with the TRICENTO bicaval valved stent for treatment of symptomatic severe tricuspid regurgitation: a multicenter registry. Circ Cardiovasc Interv. 2022;15: e011302.","journal-title":"Circ Cardiovasc Interv"},{"key":"1954_CR75","doi-asserted-by":"crossref","unstructured":"Guenther T, Noebauer C, Mazzitelli D, Busch R, Tassani-Prell P, Lange R. Tricuspid valve surgery: a thirty-year assessment of early and late outcome. Eur J Cardiothorac Surg 2008;34:402\u20139; discussion 409.","DOI":"10.1016\/j.ejcts.2008.05.006"},{"key":"1954_CR76","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1136\/heartjnl-2022-322167","volume":"109","author":"J Dreyfus","year":"2023","unstructured":"Dreyfus J, Bohbot Y, Coisne A, et al. Predictive value of the TRI-SCORE for in-hospital mortality after redo isolated tricuspid valve surgery. Heart. 2023;109:951\u20138.","journal-title":"Heart"},{"key":"1954_CR77","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jacc.2018.10.051","volume":"73","author":"DB McElhinney","year":"2019","unstructured":"McElhinney DB, Aboulhosn JA, Dvir D, et al. Mid-term valve-related outcomes after transcatheter tricuspid valve-in-valve or valve-in-ring replacement. J Am Coll Cardiol. 2019;73:148\u201357.","journal-title":"J Am Coll Cardiol"},{"key":"1954_CR78","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/j.jcin.2020.04.054","volume":"13","author":"JH Anderson","year":"2020","unstructured":"Anderson JH, McElhinney DB, Aboulhosn J, et al. Management and outcomes of transvenous pacing leads in patients undergoing transcatheter tricuspid valve replacement. JACC Cardiovasc Interv. 2020;13:2012\u201320.","journal-title":"JACC Cardiovasc Interv"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-023-01954-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-023-01954-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-023-01954-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T13:17:54Z","timestamp":1700054274000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-023-01954-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,12]]},"references-count":78,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1954"],"URL":"https:\/\/doi.org\/10.1007\/s11886-023-01954-y","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,12]]},"assertion":[{"value":"28 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"D. Meier has received an institutional grant from Edwards Lifesciences. M. Akodad is a consultant to Edwards Lifesciences and Medtronic. A. Cheung is a consultant to Medtronic, Abbott Laboratory, and Neovasc. O. Muller has received research funding from Edwards Lifesciences and is a consultant for Abbott Laboratories and Edwards Lifesciences. J. Sathananthan is a consultant to Edwards Lifesciences, Medtronic, and Boston Scientific. He has received research funding from Edwards Lifesciences and Medtronic. P. Blanke provides institutional CT core laboratory services to Edwards Lifesciences, Medtronic, Boston Scientific, Abbott Laboratories, PiCardia, Neovasc without direct personal reimbursements, and is a consultant to Edwards Lifesciences.F. Praz has received compensation for travel expenses from Abbott Vascular, Edwards Lifesciences, Polares Medical, Medira, and Siemens Healthineers. R.H. Boone is a consultant to Edwards Lifesciences and Vesalius. J. G. Webb is a consultant to, and has received research funding from, Edwards Lifesciences, Abbott, and ViVitro Labs. D. A. Wood is a consultant to, and has received research funding from, Edwards Lifesciences and Abbott. The other authors do not have any relevant disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}